Omnes Capital's investments: Octimet

Entry Date 
Venture Capital


Development of a clinically de-risked MET kinase inhibitor for the treatment of cancers

Founded in 2016, Octimet Oncology N.V. (Belgium) is a new company (spin-off from Johnson & Johnson) that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio.